The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis, and potential therapies; care considerations unique to HCT recipients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplantation centers.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, Cell therapy, Severe acute respiratory syndrome, Bone marrow transplantation, Hematopoietic cell transplantation, Immunocompromise,
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, Cell therapy, Severe acute respiratory syndrome, Bone marrow transplantation, Hematopoietic cell transplantation, Immunocompromise,